Jakavi

Novartis announces phase III study of Jakavi in chronic graft-versus-host disease met primary and key secondary endpoints
Pharmaceutical Business Review
Tue, 07/28/20 - 10:30 am
Novartis
graft vs host disease
Jakavi
FDA Grants Priority Review for Ruxolitinib (Jakafi) for Acute Graft-Versus-Host Disease
CP Wire
Thu, 10/25/18 - 09:52 am
FDA
Incyte
Novartis
Jakavi
Jakafi
graft vs host disease
3 Big Pharma Companies With the Best Pipelines
Motley Fool
Sun, 04/9/17 - 12:24 pm
JNJ
Actelion
Darzalex
Novartis
Cosentyx
Jakavi
Lucentis
Tasigna
Roche
Venclexta
Tecentriq
emicizumab
Novartis drug Jakavi seen as blockbuster after positive data
Yahoo/Reuters
Fri, 03/7/14 - 09:06 am
Novartis
Jakavi
polycythemia vera
Keep an Eye on Geron, Novartis, Cell Therapeutics, and Verastem Today
Motley Fool
Tue, 12/10/13 - 11:36 am
Verastem
Cell Therapeutics
Novartis
Geron
imetelstat
Jakavi
myelofibrosis
tosedostat
AML
VS-5584
Novartis Marrow Drug Fails to Win U.K. Agency Backing
Bloomberg
Wed, 02/13/13 - 11:04 am
Novartis
UK
Jakavi